The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands.
N Naomi van der LindenS Van OlstS NekemanC A Uyl-de GrootPublished in: Diabetic medicine : a journal of the British Diabetic Association (2020)
Dapagliflozin is a cost-saving alternative to DPP-4 inhibitors when added to metformin and sulfonylurea. The incidence of micro- and macrovascular complications is lower for people treated with dapagliflozin. Uncertainty around this outcome is low.
Keyphrases